Author Archive

Never stop reforming – six editions of Building the Bioeconomy has clear message to biotechnology policymakers around the world

Posted by:

This week I am having the pleasure of attending the 2019 BIO International Convention hosted in Philadelphia, Pennsylvania. The biggest global event of its kind, this international convention brings together stakeholders from across the biotechnologies. Whether it be from the health, agricultural or industrial sector, anyone who is anyone in biotech is in Philadelphia this week.

Every year I come to the Convention I am struck by the sheer growth in numbers. More participants; more international delegations; more interest in biotech. ...

Continue Reading →
0

Prof. Pugatch keynote speech on the “Five megatrends in the pharmaceutical industry and its implications for emerging markets”

Posted by:

Prof. Pugatch keynote speech on the “five megatrends in the pharmaceutical industry and its implications for emerging markets”, at the 19th Annual International Russian Pharmaceutical Forum, St. Petersburg, 21-23 May 2013 http://www.adamsmithconferences.com/en/event/pharma-industry-russia

Continue Reading →
0

What does the “London Declaration on Neglected Tropical Diseases” reveal about research and development efforts into neglected and tropical diseases?

Posted by:

Earlier this week the Gates Foundation, USAID, DfID, the WHO, DNDi, the Governments of Mozambique, Tanzania, Brazil and a host of multinational biopharmaceutical manufacturers including GlaxoSmithKline, Merck, Eisai, Johnson & Johnson, Sanofi, Novartis, Bayer and Abbott, committed to eradicate and control a number of neglected and tropical diseases (NTDs).

This brief will examine the declaration, the pledges made and the methods to be used. For more details click here

Continue Reading →
0

Demand Side Innovation in Europe? Dream on!

Posted by:

Demand Side Innovation in Europe? Dream on! A recent seminar organized by the Polish EU Presidency emphasized the need for supporting demand-side innovation policies in Europe, arguing that “without effective and coordinated demand-side innovation policies, Europe will find it hard to survive in the tightening competition over future business investments.” Yet at the same time, more than a decade after it was launched, many EU Member States have still not hit the basic Lisbon Agenda target of 3% of GDP ...

Continue Reading →
0

Historically confused? Google’s lawyer accuses Microsoft of abusing the patent system

Posted by:

Yet his arguments (especially about the era of steam traction innovations) are historically inaccurate. History suggests that early 19th century (and even late 18th century) patent blocking and inventing around were typical practices. Indeed the fact is that there is nothing new under the sun…just different players – read Machlup, F. An Economic Review of the Patent System, Study of the Subcommittee on Patents, Trademarks and Copyrights of the Committee on the Judiciary, United States Senate, 85th Congress, Second Session, ...

Continue Reading →
0

European biomedical innovation has left the building (much like Elvis)…

Posted by:

European Court Bans Patents Based on Embryonic Stem Cells.

Oliver Brüstle, director of the Institute of Reconstructive Neurobiology at the University of Bonn, Germany, who had a patent on a method for generating neurons from human embryonic stem cells rejected by the court, called the ruling “the worst possible outcome”, and “a disaster for Europe”.

He and other scientists worry that the ruling will cause European companies and scientists to miss out on commercial applications for embryonic-stem-cell research.

Continue Reading →
0

World’s first malaria vaccine works in major trial

Posted by:

Using IPRs effectively in neglected diseases R&D – What lessons can be learned from the positive results of the GSK and PATH’s Malaria Vaccine Initiative? Allowing partners which contribute proprietary technologies to maintain ownership and income from the end product may be key to achieving tangible results like those of the MVI. In this case, GSK, owner of many of the essential technologies of the vaccine, will supply the final product at a preferred price (cost+5%).This hybrid approach can support ...

Continue Reading →
0

Patently engaged – Microsoft vs. Google – a commercial clash or a philosophical one?

Posted by:

The dispute between Microsoft and Google over the Android operating system appears to have entered a new phase. Microsoft is reported to have signed licensing deals with 10 manufacturers who now pay a user fee for every smartphone and/or table that is sold. Google disputes the validity of Microsoft’s claims and the patents that underpin it.

The broader question remains whether or not these disputes are solely based on legal and commercial grounds, or are they part of a deeper philosophical ...

Continue Reading →
0